$MRNA
Moderna Inc Stock $mrna

$mrna Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000168285223000027 Filed on August 03, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$1.831B	$344.0M
YoY Change	-45.57%	-92.76%
Cost Of Revenue	$2.241B	$731.0M
YoY Change	103.73%	-47.07%
Gross Profit	-$410.0M	-$387.0M
YoY Change	-118.11%	-111.49%
Gross Profit Margin	-22.39%	-112.5%
Selling, General & Admin	$442.0M	$332.0M
YoY Change	58.99%	57.35%
% of Gross Profit
Research & Development	$1.160B	$1.148B
YoY Change	41.46%	61.69%
% of Gross Profit
Depreciation & Amortization	$246.0M	$92.00M
YoY Change	117.7%	21.05%
% of Gross Profit
Operating Expenses	$1.160B	$1.480B
YoY Change	41.46%	108.45%
Operating Profit	-$2.012B	-$1.867B
YoY Change	-272.56%	-176.3%
Interest Expense	$58.00M	$113.0M
YoY Change	26.09%	318.52%
% of Operating Profit
Other Income/Expense, Net	-$51.00M	$5.000M
YoY Change	628.57%	-138.46%
Pretax Income	-$1.958B	-$1.749B
YoY Change	-260.89%	-170.7%
Income Tax	$1.672B	-$369.0M
% Of Pretax Income
Net Earnings	-$3.630B	-$1.380B
YoY Change	-448.03%	-162.81%
Net Earnings / Revenue	-198.25%	-401.16%
Basic Earnings Per Share	-$9.53	-$3.62
Diluted Earnings Per Share	-$9.53	-$3.62
COMMON SHARES
Basic Shares Outstanding	380.6M shares	381.2M shares
Diluted Shares Outstanding	381.0M shares	381.0M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.573B	$8.459B
YoY Change	-9.28%	7.12%
Cash & Equivalents	$2.932B	$3.801B
Short-Term Investments	$4.641B	$4.658B
Other Short-Term Assets	$96.00M	$737.0M
YoY Change	12.94%	869.74%
Inventory	$487.0M	$715.0M
Prepaid Expenses
Receivables	$1.866B	$232.0M
Other Receivables	$280.0M	$456.0M
Total Short-Term Assets	$10.80B	$10.60B
YoY Change	-24.47%	-21.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.717B	$2.410B
YoY Change	27.44%	66.67%
Goodwill	$52.00M	$52.00M
YoY Change
Intangibles
YoY Change
Long-Term Investments	$86.00M	$6.105B
YoY Change	-99.01%	-39.92%
Other Assets	$661.0M	$2.770B
YoY Change	1639.47%	3593.33%
Total Long-Term Assets	$8.651B	$11.29B
YoY Change	-26.43%	-9.58%
TOTAL ASSETS
Total Short-Term Assets	$10.80B	$10.60B
Total Long-Term Assets	$8.651B	$11.29B
Total Assets	$19.45B	$21.88B
YoY Change	-25.35%	-15.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$494.0M	$310.0M
YoY Change	49.7%	71.27%
Accrued Expenses	$2.224B	$1.524B
YoY Change	19.83%	-14.38%
Deferred Revenue	$1.372B	$1.040B
YoY Change	-65.72%	-74.59%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$150.0M	$187.0M
YoY Change	-33.04%	54.55%
Total Short-Term Liabilities	$4.385B	$3.123B
YoY Change	-35.58%	-54.15%
LONG-TERM LIABILITIES
Long-Term Debt	$575.0M	$843.0M
YoY Change	-37.64%	31.51%
Other Long-Term Liabilities	$172.0M	$969.0M
YoY Change	112.35%	757.52%
Total Long-Term Liabilities	$172.0M	$1.812B
YoY Change	112.35%	1503.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.385B	$3.123B
Total Long-Term Liabilities	$172.0M	$1.812B
Total Liabilities	$5.995B	$4.935B
YoY Change	-25.66%	-38.76%
SHAREHOLDERS EQUITY
Retained Earnings	$13.39B	$17.02B
YoY Change	-20.56%	7.63%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.46B	$16.95B
YoY Change
Total Liabilities & Shareholders Equity	$19.45B	$21.88B
YoY Change	-25.35%	-15.97%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$3.630B	-$1.380B
YoY Change	-448.03%	-162.81%
Depreciation, Depletion And Amortization	$246.0M	$92.00M
YoY Change	117.7%	21.05%
Cash From Operating Activities	-$1.600B	-$915.0M
YoY Change	-734.92%	-400.99%
INVESTING ACTIVITIES
Capital Expenditures	$140.0M	$234.0M
YoY Change	-257.3%	-368.97%
Acquisitions
YoY Change
Other Investing Activities	$929.0M	$2.178B
YoY Change	-10.15%	-304.51%
Cash From Investing Activities	$789.0M	$1.944B
YoY Change	-16.51%	-268.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-58.00M	-668.0M
YoY Change	-94.43%	-49.66%
NET CHANGE
Cash From Operating Activities	-1.600B	-915.0M
Cash From Investing Activities	789.0M	1.944B
Cash From Financing Activities	-58.00M	-668.0M
Net Change In Cash	-869.0M	361.0M
YoY Change	-657.05%	-116.6%
FREE CASH FLOW
Cash From Operating Activities	-$1.600B	-$915.0M
Capital Expenditures	$140.0M	$234.0M
Free Cash Flow	-$1.740B	-$1.149B
YoY Change	-610.26%	-393.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Derivative Asset Statement Of Financial Position Extensible Enumeration DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2022Q4	us-gaap	Derivative Asset Statement Of Financial Position Extensible Enumeration DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q2	us-gaap	Revenues Revenues	344000000	usd
CY2022Q2	us-gaap	Revenues Revenues	4749000000	usd
	us-gaap	Revenues Revenues	2206000000	usd
	us-gaap	Revenues Revenues	10815000000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000000	usd
CY2023Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	628000000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1380000000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	16949000000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	17075000000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	9000000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50000000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-56000000	usd
CY2022Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1298000000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	2197000000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	17985000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	19123000000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	12000000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	12000000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	149000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	107000000	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1154000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1301000000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	14145000000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	20000000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	9000000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	94000000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-216000000	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1921000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5854000000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	17985000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1301000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5854000000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	149000000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	94000000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	170000000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	155000000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	29000000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-29000000	usd
	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	17000000	usd
	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	0	usd
	mrna	Deferred Income Tax Expense Benefit Net DeferredIncomeTaxExpenseBenefitNet	-530000000	usd
	mrna	Deferred Income Tax Expense Benefit Net DeferredIncomeTaxExpenseBenefitNet	-376000000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	12000000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-15000000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1153000000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-484000000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	142000000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	324000000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-234000000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	480000000	usd
	mrna	Increase Decrease In Right Of Use Asset Operating Leases IncreaseDecreaseInRightOfUseAssetOperatingLeases	9000000	usd
	mrna	Increase Decrease In Right Of Use Asset Operating Leases IncreaseDecreaseInRightOfUseAssetOperatingLeases	-20000000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-187000000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-56000000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-633000000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	305000000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-979000000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2370000000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1000000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-527000000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	12000000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-19000000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-18000000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	263000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2140000000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3067000000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1281000000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	8734000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	3264000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1409000000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2427000000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2506000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	347000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	219000000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	85000000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	23000000	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	35000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3955000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5073000000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	25000000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	29000000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1154000000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1921000000	usd
	mrna	Finance Lease Principal Payments Net Of Adjustments FinanceLeasePrincipalPaymentsNetOfAdjustments	81000000	usd
	mrna	Finance Lease Principal Payments Net Of Adjustments FinanceLeasePrincipalPaymentsNetOfAdjustments	77000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1210000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1969000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	605000000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3975000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3217000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6860000000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3822000000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2885000000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	105000000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	49000000	usd
	mrna	Right Of Use Assets Obtained Through Finance Lease Modifications And Reassessments RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments	50000000	usd
	mrna	Right Of Use Assets Obtained Through Finance Lease Modifications And Reassessments RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	94000000	usd
CY2023Q2	mrna	Number Of Development Candidates NumberOfDevelopmentCandidates	45	candidate
CY2023Q2	mrna	Number Of Development Programs NumberOfDevelopmentPrograms	47	developmentprogram
CY2023Q2	mrna	Number Of Development Programs Under Clinical Studies NumberOfDevelopmentProgramsUnderClinicalStudies	39	developmentprogram
	us-gaap	Use Of Estimates UseOfEstimates	We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, critical accounting policies or estimates related to revenue recognition, income taxes, valuation allowance of deferred tax assets, inventory valuation, firm purchase commitment liabilities, pre-launch inventory, leases, fair value of financial instruments, derivative financial instruments, useful lives of property and equipment, research and development expenses, stock-based compensation, intangible assets and goodwill. The actual results that we experience may differ materially from our estimates.
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	103000000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4000000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3801000000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	21000000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	12000000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3822000000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2885000000	usd
CY2020Q2	mrna	Number Of Participants NumberOfParticipants	30000	participant
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	4751000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	4658000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	6347000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	6105000000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	11098000000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	10763000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	6792000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	6697000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	8687000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	8318000000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	15479000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	15015000000	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	46000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	2395000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	289000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	8153000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	335000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	10548000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	241000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	7635000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	223000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	5524000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	464000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	13159000000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	467	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	582	security
CY2023Q2	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	36000000	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	17000000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	42000000	usd
CY2023Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	42000000	usd
	us-gaap	Maximum Remaining Maturity Of Foreign Currency Derivatives1 MaximumRemainingMaturityOfForeignCurrencyDerivatives1	P15M
CY2023Q2	us-gaap	Foreign Currency Cash Flow Hedge Gain Loss To Be Reclassified During Next12 Months ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months	0	usd
CY2023Q2	us-gaap	Derivative Notional Amount DerivativeNotionalAmount	691000000	usd
CY2023Q2	us-gaap	Derivative Assets DerivativeAssets	6000000	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	1000000	usd
CY2022Q4	us-gaap	Derivative Notional Amount DerivativeNotionalAmount	1488000000	usd
CY2022Q4	us-gaap	Derivative Assets DerivativeAssets	6000000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	32000000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	0	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	46000000	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	0	usd
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	71000000	usd
CY2023Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	507000000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	575000000	usd
CY2023Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	196000000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	205000000	usd
CY2023Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12000000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	169000000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	715000000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	949000000	usd
CY2023Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	723000000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	910000000	usd
CY2023Q2	us-gaap	Inventory Write Down InventoryWriteDown	464000000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	612000000	usd
CY2022Q2	us-gaap	Inventory Write Down InventoryWriteDown	499000000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	689000000	usd
CY2023Q2	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	75000000	usd
	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	141000000	usd
CY2022Q2	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	184000000	usd
	us-gaap	Inventory Firm Purchase Commitment Loss InventoryFirmPurchaseCommitmentLoss	342000000	usd
CY2023Q2	mrna	Legal Contingency Future Firm Purchase Commitments LegalContingencyFutureFirmPurchaseCommitments	220000000	usd
CY2022Q4	mrna	Legal Contingency Future Firm Purchase Commitments LegalContingencyFutureFirmPurchaseCommitments	268000000	usd
CY2023Q2	us-gaap	Inventory Gross InventoryGross	1400000000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	1900000000	usd
CY2023Q2	us-gaap	Other Inventory Capitalized Costs OtherInventoryCapitalizedCosts	183000000	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	3106000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	2676000000	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	826000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	658000000	usd
CY2023Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2280000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2018000000	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	90000000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	168000000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	76000000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	155000000	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	332000000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	216000000	usd
CY2023Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	288000000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	10000000	usd
CY2023Q2	us-gaap	Prepaid Taxes PrepaidTaxes	214000000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	187000000	usd
CY2023Q2	mrna	Other Prepaid Expense Manufacturing OtherPrepaidExpenseManufacturing	77000000	usd
CY2022Q4	mrna	Other Prepaid Expense Manufacturing OtherPrepaidExpenseManufacturing	229000000	usd
CY2023Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	62000000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	61000000	usd
CY2023Q2	mrna	Other Prepaid Expense Materials And Supplies OtherPrepaidExpenseMaterialsAndSupplies	61000000	usd
CY2022Q4	mrna	Other Prepaid Expense Materials And Supplies OtherPrepaidExpenseMaterialsAndSupplies	219000000	usd
CY2023Q2	mrna	Tenant Improvement Allowance Receivable Current TenantImprovementAllowanceReceivableCurrent	42000000	usd
CY2022Q4	mrna	Tenant Improvement Allowance Receivable Current TenantImprovementAllowanceReceivableCurrent	42000000	usd
CY2023Q2	mrna	Collaboration Receivable Current CollaborationReceivableCurrent	41000000	usd
CY2022Q4	mrna	Collaboration Receivable Current CollaborationReceivableCurrent	11000000	usd
CY2023Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	23000000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	140000000	usd
CY2023Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	36000000	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	53000000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	44000000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1193000000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1195000000	usd
CY2023Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	723000000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	910000000	usd
CY2023Q2	mrna	Downpayments And Prepayments Noncurrent DownpaymentsAndPrepaymentsNoncurrent	303000000	usd
CY2022Q4	mrna	Downpayments And Prepayments Noncurrent DownpaymentsAndPrepaymentsNoncurrent	0	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	119000000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	42000000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	52000000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	46000000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	21000000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	12000000	usd
CY2023Q2	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	26000000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	24000000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1290000000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	988000000	usd
CY2023Q2	mrna	Accrued Manufacturing AccruedManufacturing	385000000	usd
CY2022Q4	mrna	Accrued Manufacturing AccruedManufacturing	400000000	usd
CY2023Q2	mrna	Accrued Clinical Trials AccruedClinicalTrials	290000000	usd
CY2022Q4	mrna	Accrued Clinical Trials AccruedClinicalTrials	319000000	usd
CY2023Q2	mrna	Accrued Development Operation AccruedDevelopmentOperation	142000000	usd
CY2022Q4	mrna	Accrued Development Operation AccruedDevelopmentOperation	88000000	usd
CY2023Q2	mrna	Accrued Other External Goods And Services Current AccruedOtherExternalGoodsAndServicesCurrent	136000000	usd
CY2022Q4	mrna	Accrued Other External Goods And Services Current AccruedOtherExternalGoodsAndServicesCurrent	264000000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	126000000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	190000000	usd
CY2023Q2	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	70000000	usd
CY2022Q4	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	5000000	usd
CY2023Q2	mrna	Raw Materials Accounts Payable RawMaterialsAccountsPayable	62000000	usd
CY2022Q4	mrna	Raw Materials Accounts Payable RawMaterialsAccountsPayable	316000000	usd
CY2023Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	12000000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	203000000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	47000000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	48000000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1490000000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2101000000	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	187000000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	161000000	usd
CY2023Q2	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	15000000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	53000000	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	236000000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	249000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2711000000	usd
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress	140000000	usd
	mrna	Contract With Customer Liability Deductions During Period ContractWithCustomerLiabilityDeductionsDuringPeriod	1119000000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1732000000	usd
CY2023Q2	mrna	Operating Lease Number Of Properties OperatingLeaseNumberOfProperties	2	campus
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	121000000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1150000000	usd
CY2022Q4	mrna	Operating And Finance Lease Right Of Use Asset OperatingAndFinanceLeaseRightOfUseAsset	1271000000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	35000000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	161000000	usd
CY2022Q4	mrna	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	196000000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	92000000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	912000000	usd
CY2022Q4	mrna	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	1004000000	usd
CY2022Q4	mrna	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	1200000000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	20000000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	126000000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	47000000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	198000000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	20000000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	130000000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	18000000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	109000000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	19000000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	23000000	usd
CY2023Q2	mrna	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	48000000	usd
CY2023Q2	mrna	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	1097000000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	172000000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1683000000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	34000000	usd
CY2023Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	653000000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	138000000	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	1030000000	usd
CY2023Q2	mrna	Legal Contingency Future Firm Purchase Commitments LegalContingencyFutureFirmPurchaseCommitments	220000000	usd
CY2022Q2	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	157000000	usd
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	364000000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74000000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	149000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94000000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74000000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	149000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94000000	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	743000000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	8000000	shares
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	143.39
	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	1154000000	usd
CY2023Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	1667000000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1749000000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2474000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2054000000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6703000000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-369000000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	277000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-753000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	849000000	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.211
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.112
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.367
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.127
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1380000000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	2197000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1301000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	5854000000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	381000000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	396000000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	383000000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	399000000	shares
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	23000000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	24000000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	381000000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	419000000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	383000000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	423000000	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.62
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.55
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.39
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	14.66
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.62
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.39
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	13.85
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28000000	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4000000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28000000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3000000	shares
CY2023Q2	mrna	Number Of Development Programs NumberOfDevelopmentPrograms	47	developmentprogram

Files In Submission

Name	View Source	Status
0001682852-23-000027-index-headers.html	Edgar Link	pending
0001682852-23-000027-index.html	Edgar Link	pending
0001682852-23-000027.txt	Edgar Link	pending
0001682852-23-000027-xbrl.zip	Edgar Link	pending
exhibit3116302023.htm	Edgar Link	pending
exhibit3126302023.htm	Edgar Link	pending
exhibit3216302023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrna-20230630.htm	Edgar Link	pending
mrna-20230630.xsd	Edgar Link	pending
mrna-20230630_g1.jpg	Edgar Link	pending
mrna-20230630_g2.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mrna-20230630_cal.xml	Edgar Link	unprocessable
mrna-20230630_def.xml	Edgar Link	unprocessable
mrna-20230630_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
mrna-20230630_pre.xml	Edgar Link	unprocessable
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mrna-20230630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRNA
Moderna Inc Stock $mrna

2023 Q3 Form 10-Q Financial Statement

#000168285223000027 Filed on August 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA Moderna Inc Stock $mrna

2023 Q3 Form 10-Q Financial Statement

#000168285223000027 Filed on August 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA
Moderna Inc Stock $mrna